TrumpRx.gov Adds Generic Drugs and Key Private-Sector Partnerships to Maximize Healthcare Savings
The Trump administration has dramatically expanded TrumpRx.gov, adding more than 600 generic medications and integrating major pharmacy partners in a move officials say will drive down prescription drug costs and increase price transparency for millions of Americans.
The White House on May 18, 2026, announced a sweeping expansion of TrumpRx.gov, the federal government’s prescription drug price comparison platform. The update brings the total number of listed generic medications to over 600, up from fewer than 100 previously, and incorporates cash price data from Amazon Pharmacy, Mark Cuban’s Cost Plus Drugs, and GoodRx. The move is part of President Donald J. Trump’s ongoing effort to lower drug prices and provide what the administration calls “unprecedented price transparency and choice on generic medications that millions of Americans use every day.”
The expanded platform allows users to compare cash prices for common prescriptions such as atorvastatin, clopidogrel, lisinopril, and metformin at local pharmacies and through delivery options. According to the White House, the site is designed to let Americans “clearly and transparently understand the most competitive cash prices of their medications without insurance middlemen,” and to compare those prices against their insurance co-pays.
The integration of private-sector pharmacy discount programs marks a significant public-private partnership. Mark Cuban, founder of Cost Plus Drugs, said his company supplies 559 of the generics now listed on TrumpRx.gov and predicted that increased referrals from the site could further drive down prices. Amazon Pharmacy and GoodRx are also providing competitive cash prices and delivery options through the platform.
TrumpRx.gov operates as a referral platform, directing users to private-sector pharmacies and drug-pricing websites for purchases, rather than processing transactions directly. The majority of Americans still use their health insurance for prescriptions, but the administration says the platform is aimed at cash-paying consumers and those seeking to compare out-of-pocket costs.
The expansion builds on the administration’s Most-Favored-Nation (MFN) pricing initiative. On May 12, 2025, President Trump signed an executive order directing federal agencies to align U.S. drug prices with those paid by other developed nations. Letters were sent to 17 major pharmaceutical manufacturers on July 31, 2025, outlining steps to match U.S. prices to the lowest available internationally. Since then, the administration has announced 17 deals with leading manufacturers, and on December 1, 2025, reached an agreement with the United Kingdom to increase the net price of new prescription drugs by 25 percent in the U.K., aiming to ensure fairer global pricing.
Verified Price Reductions
Administration officials say the expanded TrumpRx.gov platform will drive greater cash price competition among the nation’s largest pharmacy discount companies and help Americans realize substantial savings. Price comparisons released by the White House show dramatic reductions for several high-profile medications:
| Medication | Previous Price | TrumpRx Price | Savings Example |
|---|---|---|---|
| Ozempic (monthly) | $1,028 | $350 | $678 |
| Wegovy (monthly) | $1,349 | $199–$350 | up to $1,150 |
| Gonal-F (per pen) | $1,450 | $168 | $1,282 |
| Plavix (generic) | $756 | $16 | $740 |
| Insulin Lispro | — | $25/month | — |
- $400 Million+ — Verified financial savings realized by Americans utilizing the system data.
- Up to 90% — Single-transaction price reductions documented on key chronic healthcare scripts.
- Controlled substances or assets bound to strict FDA risk metrics remain omitted from standard queries.
The Trump administration describes TrumpRx.gov as a central platform for patients to check the best cash price for their medications, with the goal of maximizing transparency and competition. The site does not offer controlled substances or drugs with FDA-mandated risk evaluation and mitigation strategies, and is open to all U.S. residents with a valid prescription.